AT17300U3 - Solid oral pharmaceutical composition - Google Patents

Solid oral pharmaceutical composition Download PDF

Info

Publication number
AT17300U3
AT17300U3 ATGM113/2020U AT1132020U AT17300U3 AT 17300 U3 AT17300 U3 AT 17300U3 AT 1132020 U AT1132020 U AT 1132020U AT 17300 U3 AT17300 U3 AT 17300U3
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
solid oral
oral pharmaceutical
disintegrant
lubricant
Prior art date
Application number
ATGM113/2020U
Other languages
German (de)
Other versions
AT17300U2 (en
Original Assignee
G L Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G L Pharma Gmbh filed Critical G L Pharma Gmbh
Priority to ATGM113/2020U priority Critical patent/AT17300U3/en
Publication of AT17300U2 publication Critical patent/AT17300U2/en
Publication of AT17300U3 publication Critical patent/AT17300U3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Feste orale pharmazeutische Zusammensetzung enthaltend Lurasidon oder ein pharmazeutisch annehmbares Salz davon, Stärke, Zuckeralkohol, ein Sprengmittel, und ein Schmiermittel.Solid oral pharmaceutical composition containing lurasidone or a pharmaceutically acceptable salt thereof, starch, sugar alcohol, a disintegrant, and a lubricant.

ATGM113/2020U 2020-12-03 2020-12-03 Solid oral pharmaceutical composition AT17300U3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ATGM113/2020U AT17300U3 (en) 2020-12-03 2020-12-03 Solid oral pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ATGM113/2020U AT17300U3 (en) 2020-12-03 2020-12-03 Solid oral pharmaceutical composition

Publications (2)

Publication Number Publication Date
AT17300U2 AT17300U2 (en) 2021-12-15
AT17300U3 true AT17300U3 (en) 2022-02-15

Family

ID=78951103

Family Applications (1)

Application Number Title Priority Date Filing Date
ATGM113/2020U AT17300U3 (en) 2020-12-03 2020-12-03 Solid oral pharmaceutical composition

Country Status (1)

Country Link
AT (1) AT17300U3 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1884242A1 (en) * 2005-05-26 2008-02-06 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical composition
EP1974724A2 (en) * 2000-09-22 2008-10-01 Dainippon Sumitomo Pharma Co., Ltd. Oral preparations with good disintegration
CN103054824A (en) * 2012-12-21 2013-04-24 北京万全德众医药生物技术有限公司 Lurasidone hydrochloride orally-disintegrating tablet preparation and preparation method thereof
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
CN106074414A (en) * 2012-07-12 2016-11-09 成都康弘药业集团股份有限公司 A kind of oral cavity disintegration tablet containing Lurasidone and preparation method thereof
CN106539768A (en) * 2015-09-18 2017-03-29 成都康弘药业集团股份有限公司 A kind of Lurasidone HCl oral cavity disintegration tablet and preparation method thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1974724A2 (en) * 2000-09-22 2008-10-01 Dainippon Sumitomo Pharma Co., Ltd. Oral preparations with good disintegration
EP1884242A1 (en) * 2005-05-26 2008-02-06 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical composition
CN106074414A (en) * 2012-07-12 2016-11-09 成都康弘药业集团股份有限公司 A kind of oral cavity disintegration tablet containing Lurasidone and preparation method thereof
CN103054824A (en) * 2012-12-21 2013-04-24 北京万全德众医药生物技术有限公司 Lurasidone hydrochloride orally-disintegrating tablet preparation and preparation method thereof
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
CN106539768A (en) * 2015-09-18 2017-03-29 成都康弘药业集团股份有限公司 A kind of Lurasidone HCl oral cavity disintegration tablet and preparation method thereof

Also Published As

Publication number Publication date
AT17300U2 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
ATE474561T1 (en) ORODISPERSIBLE PHARMACEUTICAL COMPOSITION FOR ORAL, OROMUCOSAL OR SUBLINGUAL ADMINISTRATION OF AGOMELATIN
AR109571A2 (en) COMPOSITION OF TRAZODONE FOR ADMINISTRATION ONCE A DAY
NO20084065L (en) Quick-release paracetamol tablets
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
RS53570B1 (en) Dpp iv inhibitor formulations
CY1111713T1 (en) COMPOSITION OF EXTREMELY DETAILED DISC TABLE CONTAINING PRIMPEXOLI OR A PHARMACEUTICAL SALT OF THE PRODUCTION OF PRODUCTION
EA200901393A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENES AND / OR ESTROGENS AND 5 METHYL- (6S) -TETRAHYDROPHOLATE
HUP0303325A2 (en) Pharmaceutical salts and pharmaceutical compositions containing them
JP2010047612A5 (en)
PE20110121A1 (en) PHARMACEUTICAL COMPOSITIONS OF ALISKIREN
NO20080164L (en) N- (pyridin-2-yl) -sulfonamidderivater
IL168266A (en) Nucleoside derivatives, processes for their preparation. pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments
NO20081878L (en) Diacylindazole derivatives as lipase and phospholipase inhibitors
CL2007003262A1 (en) COMPOUNDS DERIVED FROM 1,4-BENZOTIEPINA-1,1-DIOXIDE; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OF LIPID METABOLISM, HYPERLIPIDEMIA, INSULIN RESISTANCE, DIABETES AND CNS DISORDERS, BETWEEN OTHER DISEASES.
ES2579857T3 (en) Platelet rich plasma compositions
DE602004011398D1 (en) DIRECT COMPRESSIBLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF CCI-779
AR069031A1 (en) COMPOSITION
UY27549A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MELLITUS TYPE II DIABETES
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
CO6150126A2 (en) FORMULATIONS OF IMMEDIATE RELEASE TABLETS FROM A TROMBINE RECEIVER ANTAGONIST
AR115913A1 (en) BIO AVAILABLE ORAL DOSAGE FORMS, USE, METHODS
WO2019074826A3 (en) Bi-layer pharmaceutical tablet formulation
EA200500213A1 (en) DISPENSABLE TABLETS FOR ORAL APPOINTMENT
EP3866767A4 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
AT17300U3 (en) Solid oral pharmaceutical composition